Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBullfrog AI Holdings, Inc. Common Stock

Bullfrog AI Holdings, Inc. Common Stock

Healthcare Health Information Services
PortfolioPortfolio WatchlistWatchlist
Company price
0.5249 USD 0.01 ( 1.31%)
Last update at 2026-11-09T15:38:00Z
VOLUME
34790
Market Cap
17.25M

Momentum Score

…

Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.50
Low
0.54
High
52 Week Price Range
0.43
Low
2.04
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Bullfrog AI Holdings, Inc. is a NASDAQ-listed company that develops and markets artificial intelligence and analytics solutions for enterprise customers, although public disclosures and third-party coverage are limited. Long-term growth drivers may include broader enterprise adoption of AI, rising demand for automation and data-driven decision tools, and any shift toward recurring software delivery that could support revenue scalability and exposure to applied-AI trends.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.52
Dividend Yield
-
Revenue TTM
0.12M
Revenue Per Share
0.01
Gross Profit TTM
0.02M
Debt / Equity
-0.52
ROE
-183.04%
Net Debt
-2183705.00M
ROCE
-0.00%
Diluted EPS TTM
-0.63

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -6.50M -6.99M -5.36M -2.80M -0.59M
Net income -6.50M -6.99M -5.36M -2.80M -0.59M
Selling general administrative 4816790.00M 5.01M 3.99M 1.86M 0.56M
Selling and marketing expenses - - 0.00M - -
Gross profit 0.02M -0.00M 0.06M 0.01M 0.00M
Reconciled depreciation 0.00M 0.00M 0.00M 0.00M -
Ebit -6.59M -6.98M -5.28M -2.46M -0.56M
Ebitda -6.59M -6.97M -5.28M -2.45M -0.56M
Depreciation and amortization 0.00M 0.00M 0.00M 0.00M -
Operating income -6.59M -7.24M -5.37M -2.46M -0.56M
Other operating expenses 6.71M 7.24M 5.43M 2.47M 0.56M
Interest expense 0.01M 0.02M 0.08M 0.35M 0.04M
Interest income 0.10M 0.26M 0.18M - -
Net interest income 0.10M 0.24M -0.19M -0.35M -0.04M
Income tax expense - -0.04M -0.00M 0.35M -
Total revenue 0.12M 0.00M 0.07M 0.01M 0.00M
Total operating expenses 6.61M 7.24M 5.43M 2.47M 0.56M
Cost of revenue 0.10M 0.00M 0.01M 0.00M 0.00M
Total other income expense net 0.10M 0.24M 0.01M 0.00M 0.01M
Net income from continuing ops -6.50M -6.99M -4.75M -2.80M -0.59M
Net income applicable to common shares - - - - -0.59M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2808351.00M 5.55M 2.78M 0.08M 0.01M
Other current assets 400451.00M 0.11M 0.15M - -
Total liab 672022.00M 0.59M 0.18M 3.14M 1.02M
Total stockholder equity 2136329.00M 4.96M 2.59M -3.06M -1.01M
Other current liab 672021.83M 0.15M 0.08M 1.97M 0.71M
Common stock 114.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -23291624.00M -16.79M -9.75M -4.40M -1.60M
Cash 2183705.00M 5.44M 2.62M 0.06M 0.01M
Total current liabilities 672022.00M 0.59M 0.18M 3.14M 1.02M
Current deferred revenue - - - 0.03M 0.01M
Net debt -2183705.00M -5.44M -2.62M 1.52M 0.58M
Short term debt - - - 1.58M 0.59M
Short long term debt - - - 1.58M 0.59M
Short long term debt total - - - 1.58M 0.59M
Other stockholder equity 25427864.43M 21.76M 12.35M 1.34M 0.59M
Total current assets 2584156.00M 5.55M 2.77M 0.07M 0.01M
Long term investments 0.12M 0.00M - - -
Net tangible assets - - - - -1.01M
Accounts payable 0.17M 0.44M 0.10M 0.54M 0.07M
Accumulated other comprehensive income - - -0.00M - -
Non currrent assets other 105000.00M - 0.00M - -
Non current assets total 224195.00M 0.00M 0.01M 0.01M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M 0.00M -0.01M -
Change to liabilities - - - - -0.02M
Net borrowings 0.00M 0.00M -0.22M - 0.39M
Total cash from financing activities 2374987.00M 8.42M 8.57M 0.97M 0.39M
Change to operating activities - - - - 0.11M
Net income -6498068.00M -6.99M -5.36M -2.80M -0.59M
Change in cash -3147278.00M 2.81M 2.57M 0.05M 0.00M
Begin period cash flow 5435983.00M 2.62M 0.06M 0.01M 0.01M
End period cash flow 2288705.00M 5.44M 2.62M 0.06M 0.01M
Total cash from operating activities -5522265.00M -5.61M -6.00M -0.91M -0.38M
Issuance of capital stock 2.47M 8.32M 7.29M - -
Depreciation 1725.00M 0.00M 0.00M 0.00M -
Other cashflows from financing activities 2374984.63M 0.11M 1.49M 1.02M 0.39M
Change to netincome - - - - 0.09M
Capital expenditures 0.00M 0.00M 0.00M 0.01M 0.00M
Change in working capital 0.08M 0.44M -1.44M 1.14M 0.10M
Stock based compensation 1010631.00M 0.94M 0.63M 0.34M 0.10M
Other non cash items -36553.08M 0.44M 0.16M 0.41M 0.01M
Free cash flow -5522265.00M -5.61M -6.00M -0.92M -0.38M

Peer Comparison*

Sector: Healthcare Industry: Health Information Services

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BFRG
Bullfrog AI Holdings, Inc. Common Stock		 0.01
1.31%		 0.52 - - 147.82 8.47 138.46 -12.02
VEEV
Veeva Systems Inc Class A		 -1.60
0.53%		 302.12 43.49 29.59 12.48 5.79 10.39 33.41
PMCUF
Pro Medicus Limited		 -
-%		 144.00 64.90 90.91 49.11 38.05 65.12 83.47
TEM
Tempus AI, Inc. Class A Common Stock		 6.32
8.31%		 82.37 - - 8.68 25.39 8.33 -
MTHRY
M3 Inc		 0.30
5.27%		 5.99 31.84 26.25 0.05 4.60 0.04 0.12

Profile*

Bullfrog AI Holdings, Inc. Common Stock

Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.

325 Ellington Boulevard, Gaithersburg, MD, United States, 20878

240 658 6710

https://www.bullfrogai.com

9

Name Title Year Born
Mr. Vininder Singh Founder, Chairman & CEO 1970
Mr. Dane R. Saglio Chief Financial Officer 1958
Mr. J. T. Koffenberger Chief Information Officer NA
Hon. Thomas W. Chittenden X, DPHIL, Ph.D. Chief Scientific Officer NA
Dr. Cetin Savkli Ph.D. Chief AI Advisor & Member of Advisory Board NA
Mr. William Hirschman Chief Commercial Officer NA
Dr. David P. Recker FACP, FACR, M.D. Chief Medical Officer 1958
Mr. Vininder Singh Founder, Chairman & CEO 1968
Mr. Antonio V. Montano Chief Marketing Officer & Growth Strategy Leader NA
Dr. Praveen Kudithipudi M.B.A., M.D. Chief Business Development Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +3.63%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.18%

  • Financial Services

    +1.33%

  • Healthcare

    +1.49%

  • Industrials

    +2.99%

  • Real Estate

    +0.41%

  • Technology

    +1.45%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…